MAPT and Alzheimer disease: Our results and those from Nabais et al. (2021) provided additional evidence that DNA methylation at cg03546163 is also significantly hypomethylated in the blood of AD subjects16, suggesting FKBP5 methylation might be a viable candidate biomarker for tau pathology.